Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating difficult to treat
cancers, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs
survival. The increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.
In addition, despite the success of Lu-177-treatment, not all patients are responders. Around 30% of patients do not benefit from
treatment, but do suffer from side-effects.

ILLUMINATE, will improve the availability and use of theranostics across its value chain by taking a hybrid approach: 1) Imaging
capabilities will be improved by implementing novel, broadly applicable, scalable and highly effective Metabolic Magnetic Resonance
Imaging (MeMRI), which are expected to give better and faster insight into treatment responses, allowing better patient stratification
and treatment personalisation; 2) The availability of Lu-177 will be fortified by improving its manufacturing process, and by
developing sustainable production methods to help meet the general need for radio-isotope based therapies and increase EU
autonomy. The ILLUMINATE consortium uses the example of Lu-177-PSMA as a showcase for broadly applicable innovative
technologies in the field of theranostics and radioisotope manufacturing for oncology.

ILLUMINATE has 3 pillars that allow large scale development, evaluation, clinical validation, availability and adoption of improved
theranostics: 1) Technology development: MeMRI optimization and upscaling, and improved manufacturing of Lu-177; 2) Clinical
Application: MeMRI clinical study in 150 patients with metastasized prostate cancer treated with Lu-177-PSMA and Development and
testing of quantitative decision-making models 3) Adoption and healthcare integration: Patient and public Engagement & Education
for (healthcare) professionals, and Regulatory & Policy adoption.

WaveTronica B.V. will technically upgrade the MRI scanners. This allows for these scanners to be used for metabolic imaging. Metabolic imaging is expected to result in better and real-time information about treatment responses to anti-cancer therapies.

WaveTronica is very proud to be one of the 15 partners of the ILLUMINATE consortium.
UMC Utrecht, Euro-Bioimaging ERIC, Philips Medical Systems Nederland BV, Philips Gmbh Innovative Technologies, SYNLAB Italia Sdn Spa, Consiglio Nazionale delle Ricerche, University of Turin, Bracco Imaging Spa, Tesla Dynamic Coils BV, WaveTronica B.V. BV, Lund University, NRG PALLAS, Amsterdam UMC, University Hospital Essen, Lygature.